SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?


To: Howard Hoffman who wrote (1403)12/15/1997 7:58:00 AM
From: Juergen  Read Replies (1) | Respond to of 1762
 
Well you seem to be very up to speed on immunotherapy and monoclonal antibobies. AXO is a Canadian biotech firm with immunotherapeutic products in Phase 2/3 in Canada, Europe and the US,US$19 million of cash (3 years) and only US$10million of technology value. Gordon Capital has a target of CDN$7.50 on the stock and CIBC Wood Gundy has a target of CDN$6.00. Closed at CDN$2.80 Friday. Any thoughts?